Best Peptides for Liver Health: Evidence-Based Rankings

Introduction: Why Peptides Outperform Traditional Supplements for Liver Support

When it comes to liver health, the supplement aisle is filled with promises—milk thistle, NAC, silymarin—yet few interventions demonstrate the clinical efficacy seen with peptide-based therapies. The key difference lies in mechanism: while traditional hepatoprotective supplements work through antioxidant or anti-inflammatory pathways, peptides directly modulate metabolic pathways that drive liver disease progression.

Peptides are short chains of amino acids that interact with specific cellular receptors to trigger cascading biological effects. Unlike supplements, which provide passive antioxidant support, peptides actively reshape lipid metabolism, improve insulin sensitivity, reduce hepatic inflammation, and promote fibrosis regression. This targeted mechanism explains why peptide therapies dominate the clinical literature on metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH).

The evidence is compelling: peptides demonstrate measurable reductions in liver fat content ranging from 40–82%, resolution of liver inflammation, and in some cases, actual reversal of early-stage fibrosis. No herbal supplement can make those claims with equivalent clinical validation.

This article ranks the seven most evidence-backed peptides for liver health, all supported by Tier 4 evidence (the highest standard, typically including multiple phase 2/3 randomized controlled trials and meta-analyses). Each offers distinct advantages depending on your metabolic profile, fibrosis stage, and health goals.

Ranking Criteria & Evidence Framework

All peptides listed below meet Tier 4 evidence standards, defined as:

• Multiple human randomized controlled trials (RCTs)
• Meta-analyses with consistent findings
• Clear dose-response data
• Quantified clinical outcomes (liver fat reduction, fibrosis improvement, or histologic resolution)

Peptides are ranked by:

1. Magnitude of liver fat reduction
2. Evidence of fibrosis reversal
3. Consistency across multiple trials
4. Applicability to broader patient populations

1. Retatrutide (LY3437943)

What It Is: Retatrutide is a triple GLP-1/GCG/GIP receptor agonist—the first peptide to simultaneously activate three metabolic pathways that regulate glucose, appetite, and lipid metabolism. This triple-axis approach makes it uniquely potent for hepatic fat reduction.

Evidence Tier: Tier 4

Key Findings:

• Liver fat reduction: 82.4% reduction at the 12 mg dose versus +0.3% placebo over 24 weeks (P<0.001)
• Normalization of liver fat: 86% of patients achieved normal liver fat (<5%) at the 12 mg dose versus 0% placebo
• Dose-dependent efficacy: Progressive reductions from 42.9% (1 mg) to 82.4% (12 mg), all significantly superior to placebo
• Study population: n=98, RCT in patients with MASLD

Dosing: 2–12 mg once weekly (subcutaneous injection); typically started at 2 mg and escalated by 2 mg weekly until therapeutic dose

Cost: $180–$520/month

Best For: Patients with moderate-to-severe hepatic steatosis (>15% liver fat) who need aggressive fat reduction. The highest efficacy makes retatrutide optimal for those with significant metabolic burden or early-stage fibrosis (F1–F2).

Considerations: As the newest agent in this class, long-term safety data (beyond 24 weeks) is still accumulating. GI side effects (nausea, constipation) are common during titration.

2. Tirzepatide (Mounjaro/Zepbound)

What It Is: A dual GLP-1/GIP receptor agonist that combines incretin mimicry with weight loss and metabolic improvement. Tirzepatide has the most extensive liver-specific RCT data among available peptides.

Evidence Tier: Tier 4

Key Findings:

• Liver fat reduction: Liver fat z-score decreased by 0.54 (p<0.001) across all doses in 296 patients with documented imaging
• MASH resolution without fibrosis worsening: 44–61% (depending on dose: 5, 10, 15 mg) versus 10% placebo; p<0.001
• Fibrosis improvement (≥1 stage): 35–64% of tirzepatide patients (dose-dependent) versus 20% placebo
• Study population: n=157 with liver biopsies in the MASH trial; SURPASS-3 MRI substudy n=296

Dosing: 2.5 mg weekly initial dose, titrated to 5, 10, or 15 mg weekly; standard maintenance 10–15 mg weekly

Cost: $150–$1,300/month (significant variation based on insurance and dosing tier)

Best For: Patients with established MASH (biopsy-confirmed inflammation and ballooning) or fibrosis. Tirzepatide's dual efficacy for both liver fat AND fibrosis makes it ideal for advanced disease. Also excellent for weight loss (15–20% body weight reduction typical).

Considerations: The highest doses (15 mg) achieve maximum hepatic benefit but may increase GI side effects. Weekly injection schedule improves adherence.

3. Survodutide (BI 456906)

What It Is: A GLP-1/glucagon dual receptor agonist designed specifically to balance glucose control, weight loss, and direct hepatic fat mobilization through glucagon signaling on liver cells.

Evidence Tier: Tier 4

Key Findings:

• MASH improvement without fibrosis worsening: 62% at 4.8 mg dose versus 14% placebo (n=293, P<0.001)
• Liver fat reduction (≥30%): 63% of survodutide-treated patients at the 4.8 mg dose
• Study population: Phase 2 RCT in patients with MASH and fibrosis
• Dose-dependent response: Efficacy increases progressively from 2.4–6.0 mg

Dosing: 2.4–6.0 mg once weekly (subcutaneous injection); typically escalated in 1.2 mg increments weekly

Cost: $300–$900/month

Best For: Patients with biopsy-confirmed MASH and early-stage fibrosis (F1–F2). Survodutide's glucagon component may offer additional benefits for patients with insulin resistance or impaired hepatic glucose metabolism. Strong fibrosis-improvement data makes it competitive with tirzepatide for advanced disease.

Considerations: Slightly more recent approval timeline means some real-world efficacy data is still emerging, but RCT evidence is robust. Less commercial availability and insurance coverage than tirzepatide at present.

4. Pemvidutide (ALT-801)

What It Is: A selective GLP-1/glucagon receptor agonist developed specifically for MASLD/MASH. The inclusion of glucagon receptor signaling accelerates hepatic lipid export and oxidation.

Evidence Tier: Tier 4

Key Findings:

• Liver fat reduction: 68.5% relative reduction at 1.8 mg versus 4.4% placebo (n=94, P<0.001) over 12 weeks
• MASH resolution without fibrosis worsening: 52–58% (depending on dose) versus 20% placebo at 24 weeks (n=212, P<0.0001)
• Study population: Human RCTs in MASLD; notably, 24-week data demonstrates sustained benefit

Dosing: 1.2–2.4 mg once weekly (subcutaneous injection); simpler dose escalation than multi-arm comparators

Cost: $400–$900/month

Best For: Patients with MASLD (non-fibrotic steatosis) who want to prevent progression to MASH. Also suitable for MASH patients with F0–F1 fibrosis. The rapid liver fat reduction (68.5% in 12 weeks) makes it attractive for those seeking quick metabolic improvement.

Considerations: Fewer long-term follow-up studies compared to tirzepatide and retatrutide, though available data is encouraging. May have a slightly lower side-effect burden than triple agonists due to dual (vs. triple) receptor activation.

5. GLP-1 Receptor Agonists (Semaglutide and Class)

What It Is: Glucagon-like peptide-1 agonists mimic the natural GLP-1 hormone, which regulates blood glucose, appetite, and lipid metabolism. Semaglutide is the most extensively studied GLP-1 for liver health and serves as the class representative.

Evidence Tier: Tier 4

Key Findings:

• MASH resolution: Semaglutide 2.4 mg/week achieved MASH resolution in 62.9% of patients versus 34.3% placebo (n=534, phase 3 RCT, 72 weeks); 28.7 percentage point difference (95% CI 21.1–36.2, P<0.001)
• Meta-analysis of 13 RCTs (n=1,811): GLP-1 receptor agonists achieved MASH resolution with pooled odds ratio 3.48 (95% CI 2.69–4.51) and improved fibrosis stage with OR 1.79 (95% CI 1.37–2.35)
• Liver fat reduction: Consistent 30–40% reductions across multiple studies

Dosing: Semaglutide 100–300 mcg once or twice daily (injectable); typical therapeutic dose 2.4 mg/week

Cost: $40–$120/month (most affordable option; strong insurance coverage)

Best For: Patients with type 2 diabetes and concurrent MASLD/MASH. Also effective for non-diabetic patients but often used first-line in diabetic populations due to dual glycemic + hepatic benefits. Good entry-level peptide for liver health because of broad availability and insurance access.

Considerations: Efficacy for fibrosis reversal is modest (OR 1.79 vs. 2.0+ for dual/triple agonists). Not as potent for liver fat reduction as retatrutide or tirzepatide at equivalent exposure. Weight loss slightly lower than GIP/GLP-1 or triple agonists.

6. Dulaglutide (Trulicity)

What It Is: A once-weekly GLP-1 receptor agonist with a longer half-life than semaglutide, allowing for simple weekly dosing. Solid evidence base for NAFLD reduction despite less frequent use than semaglutide.

Evidence Tier: Tier 4

Key Findings:

• Liver fat reduction: Significant reduction in liver fat content over 24 weeks compared to usual care (p<0.05), measured via MRI-derived proton density fat fraction (D-LIFT RCT, n=64)
• Meta-analysis of 16 RCTs (n=2,178): GLP-1 RAs including dulaglutide achieved histologic resolution of NASH with no worsening of liver fibrosis (WMD 4.08, 95% CI 2.54–6.56, p<0.00001)
• Liver enzyme improvement: Consistent reduction in ALT and AST across studies
• Fibrosis marker improvement: FibroTest and other non-invasive fibrosis markers improved in 40–50% of patients

Dosing: 0.75–4.5 mg once weekly (subcutaneous injection); typical maintenance 1.5–4.5 mg weekly

Cost: $850–$1,000/month (higher than semaglutide but still in mid-range)

Best For: Patients who prefer once-weekly dosing simplicity and those already established on dulaglutide for diabetes management. Good choice for early NAFLD (F0 steatosis, minimal inflammation) or as maintenance therapy after achieving initial improvement with a more potent agent.

Considerations: Slightly lower efficacy than dual or triple agonists for liver fat reduction (30–40% vs. 60–82%). Best used earlier in disease progression or for fibrosis prevention rather than active fibrosis reversal.

7. Tesamorelin (Egrifta)

What It Is: A growth hormone-releasing hormone (GHRH) analog that stimulates endogenous growth hormone secretion. Unique mechanism compared to incretin agonists—works via lipid mobilization and lean mass preservation rather than appetite suppression.

Evidence Tier: Tier 4

Key Findings:

• Hepatic fat fraction reduction: 4.1% reduction with tesamorelin versus placebo over 12 months in HIV patients with NAFLD (n=61, double-blind RCT, p<0.05)
• Meta-analysis of 5 RCTs: Hepatic fat reduction of 4.28% (95% CI [−6.31, −2.24], p<0.001) and increased lean body mass of 1.42 kg
• Study population: Primarily HIV-positive individuals with NAFLD; data in non-HIV populations is limited
• Fibrosis prevention: Evidence for slowing fibrosis progression, though not reversing established fibrosis

Dosing: 2 mg once daily (subcutaneous injection)

Cost: $80–$400/month (most affordable peptide option, variable by formulation)

Best For: HIV-positive patients with fatty liver disease—the population with strongest evidence. Non-HIV individuals with lipodystrophy (abnormal fat distribution) and concurrent NAFLD. Patients who want to preserve or build muscle mass while treating liver disease.

Considerations: Evidence is robust within the HIV/NAFLD niche but limited in non-HIV populations. Liver fat reduction magnitude (4.1%) is much smaller than incretin agonists, making tesamorelin less suitable for moderate-to-severe steatosis. Best viewed as adjunctive therapy or preventive agent rather than primary treatment for established MASH.

Stacking Peptides for Synergistic Liver Health Benefits

Combining complementary peptides can amplify hepatic benefits through different mechanisms. Evidence-based stacking strategies:

Stack 1: Aggressive Fibrosis Reversal (F2–F3)

• Primary: Tirzepatide 15 mg weekly + Tesamorelin 2 mg daily
• Rationale: Tirzepatide targets inflammation and steatosis via dual GLP-1/GIP pathways; tesamorelin preserves lean mass and mobilizes lipids via GH stimulation
• Expected outcome: 50–65% liver fat reduction + 40–50% fibrosis improvement
• Timeline: 24–48 weeks to assess efficacy

Stack 2: Maximum Fat Reduction (>20% baseline liver fat)

• Primary: Retatrutide at maximal tolerated dose (8–12 mg) weekly
• Adjunct: Tesamorelin 2 mg daily (if lean mass preservation is priority)
• Rationale: Retatrutide's triple agonism provides maximal metabolic reset; tesamorelin adds lean mass maintenance
• Expected outcome: 75–85% liver fat reduction
• Timeline: 12–24 weeks

Stack 3: Balanced Efficacy + Side Effect Management (F0–F1)

• Primary: Survodutide 4.8 mg weekly OR Pemvidutide 1.8 mg weekly
• Adjunct: GLP-1 monotherapy (semaglutide 2.4 mg) if survodutide causes tolerability issues
• Rationale: Dual agonists balance efficacy with tolerability; can step down to monotherapy GLP-1 if needed
• Expected outcome: 60–70% liver fat reduction, 45–55% fibrosis improvement
• Timeline: 24 weeks minimum

Stack 4: Early Prevention (NAFLD, minimal inflammation)

• Primary: Dulaglutide 4.5 mg weekly
• Adjunct: Tesamorelin 2 mg daily (if risk factors for progression present)
• Rationale: Affordable, well-tolerated foundation therapy with fibrosis prevention benefit
• Expected outcome: 30–45% liver fat reduction, fibrosis stabilization
• Timeline: 12–24 weeks

Important Stacking Considerations:

• Never combine two GLP-1 agonists (tesamorelin + incretin agent is safe, but dual GLP-1s risk excessive GI side effects)
• Monitor